You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

BRCA1 and/or other HRD-associated mutation

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Breast Cancer, Ovarian Cancer, Pancreas Cancer Trial (TNG348, Olaparib)

Not yet recruiting
  • Breast Cancer
  • +7 more
  • (no location specified)
Sep 26, 2023

Metastatic Castration-resistant Prostate Cancer Trial in Guangzhou (Pamiparib)

Recruiting
  • Metastatic Castration-resistant Prostate Cancer
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Apr 7, 2022

Advanced Breast Cancer, HER2/Neu Negative, Triple-Negative Breast Cancer Trial in Stanford (Talazoparib Tosylate)

Active, not recruiting
  • Advanced Breast Cancer
  • +2 more
  • Talazoparib Tosylate
  • Stanford, California
    Stanford University Hospitals and Clinics
Nov 16, 2022

BRCA1 Gene Mutation, BRCA2 Gene Mutation, Ovarian Serous Adenocarcinoma Trial in Buffalo, New York (biological, other, drug)

Active, not recruiting
Has Results
  • BRCA1 Gene Mutation
  • +5 more
  • Durvalumab
  • +3 more
  • Buffalo, New York
  • +1 more
Jan 20, 2023

HR Genes and the HRD Status in Chinese Epithelial Ovarian Cancer

Completed
  • Epithelial Ovarian Cancer
  • +6 more
  • Evaluation of homologous recombination deficiency score
  • Beijing, Beijing, China
    Lei Li
Mar 26, 2022

BRCA1 Mutation, BRCA2 Mutation, Ovarian Cancer Trial in Providence (Talazoparib Oral Capsule)

Active, not recruiting
  • BRCA1 Mutation
  • +4 more
  • Talazoparib Oral Capsule
  • Providence, Rhode Island
  • +1 more
Nov 30, 2022

Endocrine Disruptors and Life STILe in Breast Cancer Development

Recruiting
  • Breast Cancer
  • +5 more
    • Roma, Italy
      Alessandra Fabi
    Feb 25, 2023

    Advanced Malignant Tumor, ATM Gene Mutation, BRCA1 Gene Mutation Trial in Houston (Laboratory Biomarker Analysis,

    Active, not recruiting
    • Advanced Malignant Neoplasm
    • +7 more
    • Laboratory Biomarker Analysis
    • +2 more
    • Houston, Texas
      M D Anderson Cancer Center
    Feb 21, 2022

    TNBC - Triple-Negative Breast Cancer, BRCA1 Mutation, BRCA2 Mutation Trial (olaparib, Durvalumab)

    Not yet recruiting
    • TNBC - Triple-Negative Breast Cancer
    • +2 more
    • (no location specified)
    Jan 12, 2022

    Pancreatic Adenocarcinoma Metastatic, BRCA1 Mutation, BRCA2 Mutation Trial in Boston, New York (Melphalan, BCNU, Vitamin B12B)

    Recruiting
    • Pancreatic Adenocarcinoma Metastatic
    • +14 more
    • Boston, Massachusetts
    • +1 more
    Dec 6, 2022

    Triple Negative Breast Tumors, Triple Negative Breast Cancer, Breast Tumors Trial (Pembrolizumab, Paclitaxel, Carboplatin)

    Not yet recruiting
    • Triple Negative Breast Neoplasms
    • +7 more
    • (no location specified)
    Aug 1, 2022

    Prostate Adenocarcinoma, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8 Trial (Biospecimen Collection,

    Not yet recruiting
    • Prostate Adenocarcinoma
    • +2 more
    • Biospecimen Collection
    • +6 more
    • (no location specified)
    Mar 28, 2023

    BRCA1/2 Mutation Trial in Philadelphia (INO-5401, INO-9012, Cellectra 2000)

    Recruiting
    • BRCA1/2 Mutation
    • Philadelphia, Pennsylvania
      University of Pennsylvania
    Dec 7, 2021

    Germline Mutations Associated With Hereditary Pancreatic Cancer

    Recruiting
    • Pancreatic Cancer
    • Pancreatic Adenocarcinoma
    • Invitae Multi-Cancer Panel ®
    • Mexico City, Mexico
      Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubi
    Mar 22, 2022

    Metastatic Breast Cancer, Locally Advanced Breast Cancer, Advanced Breast Cancer Trial in Philadelphia (Palbociclib, Olaparib,

    Recruiting
    • Metastatic Breast Cancer
    • +4 more
    • Philadelphia, Pennsylvania
      Abramson Cancer Center of the University of Pennsylvania
    Jul 20, 2021

    An Imaging Study of FCH-PET-CT in Prostate Cancer andBRCA Gene

    Recruiting
    • Prostate Cancer
    • +2 more
    • MRI pelvis or CT imaging
    • +2 more
    • London, Sutton, Surrey, United Kingdom
      Cancer Genetics Unit, Royal Marsden Hospital
    Mar 30, 2022

    Deleterious BRCA1 Gene Mutation, Deleterious BRCA2 Gene Mutation, Ductal Breast Carcinoma In Situ Trial in Houston (Behavioral,

    Active, not recruiting
    • Deleterious BRCA1 Gene Mutation
    • +5 more
    • Behavioral, Psychological or Informational Intervention
    • Questionnaire Administration
    • Houston, Texas
      M D Anderson Cancer Center
    Sep 22, 2022

    Breast Cancer After Ovarian Cancer During and/or After Therapy:

    Recruiting
    • BRCA-Associated Breast Carcinoma
    • Next-generation sequencing (NGS) assay TruSight Oncology 500 (TSO 500).
    • Rome, RM, Italy
      Fondazione Policlinico Universitario Agostino Gemelli IRCCS
    Mar 9, 2023

    ER-positive and HER2-negative Metastatic or Locally Advanced Breast Cancer, a Germline or Somatic BRCA Mutation, or a

    Recruiting
    • ER-positive and HER2-negative Metastatic or Locally Advanced Breast Cancer
    • a Germline or Somatic BRCA Mutation, or a Deleterious Alteration of Other Genes Involved in Homologous Recombination Repair (HRR) or in MSI Status
    • Montpellier, France
    • +1 more
    Nov 16, 2022

    Breast Tumors Trial in Worldwide (KU-0059436 (AZD2281) (PARP inhibitor))

    Completed
    Has Results
    • Breast Neoplasms
    • KU-0059436 (AZD2281) (PARP inhibitor)
    • West Hollywood, California
    • +16 more
    Jan 24, 2023

    BRCA1 Gene Mutation, BRCA2 Gene Mutation, Locally Advanced Solid Tumor Trial in New Brunswick, New York (Laboratory Biomarker

    Recruiting
    • BRCA1 Gene Mutation
    • +19 more
    • Laboratory Biomarker Analysis
    • Pembrolizumab
    • New Brunswick, New Jersey
    • +1 more
    Nov 16, 2022

    Pancreatic Cancer Trial in Philadelphia (RUCAPARIB)

    Active, not recruiting
    • Pancreatic Cancer
    • Philadelphia, Pennsylvania
      Abramson Cancer Center of the University of Pennsylvania
    Nov 10, 2021

    BRCA1 Gene Mutation, BRCA2 Gene Mutation, Folate Receptor Alpha Positive Trial in Columbus (other, biological, drug)

    Active, not recruiting
    • BRCA1 Gene Mutation
    • +9 more
    • Laboratory Biomarker Analysis
    • +3 more
    • Columbus, Ohio
      Ohio State University Comprehensive Cancer Center
    Sep 16, 2022

    Breast Cancer Trial in France (Main study:, Sub-study:)

    Recruiting
    • Breast Cancer
    • Main study:
    • Sub-study:
    • Bordeaux, France
    • +20 more
    Jan 2, 2023

    Metastatic Breast Cancer With BRCA 1 or BRCA 2 Genetic Mutation, Triple-Negative Breast Cancer Trial in Seattle (Veliparib,

    No longer available
    • Metastatic Breast Cancer With BRCA 1 or BRCA 2 Genetic Mutation
    • Triple-Negative Breast Cancer
    • Seattle, Washington
      Seattle Cancer Care Allliance
    Jul 14, 2021